Acute respiratory failure on a low dose of amiodarone - is it an underdiagnosed and undertreated condition?

Mijo Meter1, Ivana Kuzmić Prusac2, Duška Glavaš1

  • 1Department of Cardiology, University Hospital Centre Split, Spinčićeva 1, 21000, Split, Croatia.

Insights

Amiodarone-induced pulmonary toxicity (AIPT) can cause acute respiratory failure, even at low doses. Early diagnosis and risk factor identification are crucial for managing this rare but serious condition.

Area of Science:

  • Pulmonology
  • Cardiology
  • Pharmacology

Background:

  • Amiodarone is an antiarrhythmic drug used for atrial fibrillation.
  • Amiodarone-induced pulmonary toxicity (AIPT) is a rare but serious adverse effect.
  • AIPT can present with diverse clinical manifestations.

Observation:

  • A patient with paroxysmal atrial fibrillation developed acute respiratory distress syndrome.
  • The patient was on a low dose of amiodarone.
  • No specific risk or precipitating factors for AIPT were identified in this case.

Findings:

  • Amiodarone use was rarely associated with acute respiratory failure.
  • Diagnosis of AIPT was confirmed after amiodarone discontinuation and exclusion of other causes.
  • Acute respiratory failure due to AIPT is often underdiagnosed and undertreated.

Implications:

  • Better identification of risk factors for AIPT is needed.
  • Development of diagnostic tools for risk stratification in patients on amiodarone is mandatory.
  • Increased awareness can improve diagnosis and treatment of AIPT.

Related Concept Videos

Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
424
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
393
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
285
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
445
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
238
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
77